Dynamic markers, such as thyroglobulin doubling rate, metastatic tumor volume-doubling rate, and immunological indicators, such as the neutrophil-to-lymphocyte ratio, are useful for predicting the prognosis and evaluating the effectiveness of treatments, such as radioactive iodine therapy and molecular targeted therapy for recurrent lesions. The gene discussed is TG; the disease is metastatic neoplasm.